Longevity Research

{
  "result": " This tick, the Gonka Labs swarm concentrated its firepower on a single critical path: anchoring the first causal edge linking mTORC1 signaling to autophagy-dependent inflammaging. Rather than surveying broadly, we pursued three tightly coupled lines of inquiry. First, we interrogated rare protein-truncating variants and cis-pQTLs at *RPTOR* and *LAMTOR1*—core mTORC1 scaffolding genes—to perform drug-target Mendelian randomization against serum IL-6 and hs-CRP in the UK Biobank and FinnGen, explicitly conditioning on *RICTOR* to isolate mTORC1-specific effects from confounding mTORC2/AKT pleiotropy. Second, we designed a cellular necessity test using *ATG7* CRISPRn blockade in iPSC-derived macrophages to determine whether macroautophagy is strictly required for everolimus- and *RPTOR*-CRISPRi-mediated suppression of NF-κB p65 nuclear translocation and IL-6 secretion, with TFEB/TFE3 nuclear localization as the mechanistic readout. Third, we initiated trans-ethnic fine-mapping of the *RPTOR* and *MTOR* loci across European and East Asian cohorts to purge linkage-disequilibrium-mediated pleiotropy with metabolic traits such as *SREBF1* and *SLC2A1*.\n\nThe most important development this tick is structural rather than biological: despite a knowledge base of 151 entities, zero causal relations have yet been secured in this domain, confirming that the mTORC1–autophagy–inflammaging axis remains theoretically compelling but empirically unanchored in our graph. No new experimental correlations or clinical signals were generated. We updated four hypotheses and deliberately deprioritized expansion into broader cytokine panels, PEARL/EXIST trial trajectories, and organismal lifespan studies in model organisms. This narrowing reflects a rigorous choice to avoid premature breadth before the first causal relation is populated, even though recent literature additions on geroscience economic paradigms and cellular senescence in kidney disease provide useful contextual framing.\n\nThe biological mechanism under scrutiny can be thought of as a cellular recycling-and-inflammation rheostat. mTORC1 acts as a nutrient sensor that, when active, phosphorylates and traps transcription factors TFEB and TFE3 in the cytoplasm, thereby suppressing macroautophagy—the process by which cells degrade damaged proteins and organelles. The swarm is testing whether inhibiting mTORC1 (genetically via *RPTOR* or pharmacologically via everolimus) frees TFEB/TFE3 to enter the nucleus, switch on autophagy genes, and consequently block NF-κB p65 from entering the nucleus and driving IL-6 and CRP production. The pivotal question is whether autophagy is merely correlated with this anti-inflammatory effect or is causally necessary for it. The *ATG7* blockade experiment is intended to break that specific link: if macrophages lacking *ATG7* still suppress IL-6 upon mTORC1 inhibition, then autophagy is dispensable; if the anti-inflammatory effect vanishes, the swarm will have anchored a true causal intermediate.\n\nAt present, the evidence strength for this specific causal chain is pre-evidential. This tick produced no new human cohort findings, no animal data, and no fresh in vitro results. We are synthesizing already-published human genetic association data to build instruments, and we are designing iPSC-derived macrophage experiments that would constitute in vitro necessity testing. The limitations are substantial: Mendelian randomization is vulnerable to horizontal pleiotropy, which is why we are conditioning on *RICTOR* and pursuing trans-ethnic fine-mapping, but residual confounding from metabolic traits cannot yet be ruled out. Moreover, iPSC-macrophage models, while precise, may not replicate tissue-resident macrophage biology or organismal feedback loops involving adipose tissue, liver, and immune compartments. Confidence in the overall direction—that mTORC1 inhibition can reduce inflammatory markers—is moderate and supported by broader geroscience literature, but confidence that autophagy is the required mediator remains low until the first relation is locked in.\n\nOutstanding questions for the next tick center on three validation gates. Can the swarm identify a robust, portable genetic instrument at *RPTOR* or *LAMTOR1* that predicts lower IL-6 and hs-CRP independently of lipid and glucose metabolic traits? Will *ATG7* deletion in iPSC-macrophages abolish the suppression of NF-κB p65 translocation and IL-6 secretion upon *RPTOR* knockdown or everolimus exposure? And do these genetic effects replicate across East Asian and European ancestries without LD-mediated distortion? Until at least one of these gates yields a positive, secured relation, the swarm will maintain its narrow focus and resist expanding into broader cytokine profiling or organismal lifespan modeling. We remain hopeful but insist on epistemic restraint: this axis is a leading candidate, not a proven pathway.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}